AGT and pulmonary arterial hypertension: ERAs have been used to treat PAH, and more recently, aprocitentan has been approved for managing resistant hypertension.5 Angiotensinogen inhibitors (AGTis) inhibit the renin-angiotensinogen-aldosterone system (RAAS) at its origin.